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A B S T R A C T
Androgen deprivation therapy (ADT) is the mainstay treatment for advanced prostate cancer (PC). Most patients
eventually progress to a condition known as castration-resistant prostate cancer (CRPC), characterized by lack of
response to ADT. Although new androgen receptor signaling (ARS) inhibitors and chemotherapeutic agents have
been introduced to overcome resistance to ADT, many patients progress because of primary or acquired re-
sistance to these agents. This comprehensive review aims at exploring the mechanisms of resistance and pro-
gression of PC, with specific focus on alterations which lead to the activation of androgen receptor (AR)-in-
dependent pathways of survival. Our work integrates available clinical and preclinical data on agents which
target these pathways, assessing their potential clinical implication in specific settings of patients. Given the
rising interest of the scientific community in cancer immunotherapy strategies, further attention is dedicated to
the role of immune evasion in PC.
1. Introduction
Prostate cancer (PC) accounts for 1 in 5 new diagnoses of cancer in
the United States of America and, despite the recent improvements, this
neoplasm still causes more than 26,000 deaths per year (Siegel et al.,
2016). The prostate gland is constituted both of basal and luminal
epithelium arranged in a fibro-muscular stromal network (Packer and
Maitland, 2016). Based on the observation that human PC are mostly
luminal-like adenocarcinomas, the luminal origin of PC is supported by
several studies (Wang et al., 2009; Wang et al., 2014). However, the
basal cell transformation into tumorigenic luminal cells is also sug-
gested as an alternative origin of PC (Packer and Maitland, 2016).
Differently from basal cells, the luminal secretory cells of normal
prostate require androgens for survival and undergo apoptosis upon
androgen withdrawal (Long et al., 2005). Therefore, the androgen re-
ceptor (AR) has been historically considered the most relevant target to
control the growth and dissemination of PC and this notion has guided
the treatment of PC for several years (Watson et al., 2015). The time has
probably come for this paradigm to be changed. First, not all hormone-
naïve PC appear to be equally responsive to androgen deprivation
therapy (ADT). Recently, Feng et al. segregated more than 3500 PC
samples into luminal A, luminal B, and basal subtypes using the PAM50
classifier, which distinguishes basal and luminal breast cancers, and
showed that only luminal B PC are significantly associated with post-
operative response to ADT (Feng et al., 2017). Second, the high fre-
quency of AR aberrations, found in highly pretreated patients with PC,
suggests that AR probably acts as the main driver of proliferation and
progression in some of these patients too, but this observation does not
tell the whole story (Robinson et al., 2015). In fact, the poorly differ-
entiated and aggressive PC cells show low levels of AR and prostate
specific antigen (PSA) expression and sustain proliferation and invasion
in a completely hormone-independent manner (Ellis and Loda, 2015;
Miyamoto et al., 2015). Stemness signatures, self-renew capacity, re-
sistance to immune-response, phenotypic plasticity and lack of contact
inhibition are the main characteristics of these clones, which are re-
fractory to therapies, exhibit high clonogenic potential, and show long-
term tumor-propagating capacity (Boyd et al., 2012; Ellis and Loda,
2015; Mahal et al., 2016; Qin et al., 2012; Roubaud et al., 2016). These
cells may be the result of multiple genetic and phenotypic alterations
induced by treatments, but may also represent pre-existing
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subpopulations, which are selected based on their ability to survive in
adverse conditions. Genomic rearrangements, rare mutations and epi-
genetic phenomena amplify transcriptomic diversity of PC, converging
on specific cellular functions and AR-independent signaling pathways
of survival and proliferation (Wyatt et al., 2013) (Fig. 1). Therefore,
primary or acquired resistance to treatments is probably the result of
the extensive genetic diversity and heterogeneity of PC rather than of a
linear evolutionary process (Boyd et al., 2012; Liu et al., 2015). In
addition to genetic or epigenetic events that occur in tumor cells, a
favorable local microenvironment is an invariable prerequisite for the
growth and the dissemination of this neoplasm (Barron and Rowley,
2012). Chemo-hormonal and mechanical signals modulate the behavior
Fig. 1. The iceberg of resistance in PC. The AR alterations (i.e. mutations, amplifications, truncations) only represent the tip of the iceberg. Below we report a selection of AR-independent
pathways potentially involved in the resistance of PC cells to treatments. Several drugs are currently available for inhibiting these pathways. Clockwise: (A) Divergent clonal evolution
from CRPC adenocarcinoma cells is implicated in the development of NEPC; alisertib is effective in tumors which harbor amplifications of MYCN and AURKA. (B) IL-6 promotes PC cell
proliferation and induces EMT through multiple signal pathways, including the JAK-STAT and the ERK-MAPK pathway. (C) Several components of the ECM influence the tumor
microenvironment and activate the RAF-MEK-ERK kinase cascade and the PI3K-AKT-mTOR pathway. The hypoxia pathway is intimately connected with the PI3K-AKT-mTOR pathway.
As shown, sorafenib, MEK inhibitors, buparlisib, ipatasertib and mTOR inhibitors are all potential modulators of these signaling pathways. (D) Palbociclib and ribociclib inhibit CDKs,
inducing the blockade of cell cycle progression. (E) TGFβ exerts pleiotropic actions on immune cells and promote angiogenesis in PC; a models suggests that tumor cells may become
resistant to TGFβ trough inactivation of TGFβ receptor or SMAD activity (Pickup et al., 2013). (F) Notch shows both tumor suppressive and oncogenic roles in PC, inducing the activation
of several transcription factors. (G) Canonical (β-catenin-dependent) and non-canonical (RHOA, ROCK and JNK dependent) Wnt signaling exerts proliferative effects on tumor cells. ERG
activates YAP transcriptional program and YAP/TAZ pathway acts on Wnt signaling. Tankyrase inhibitors, statins, NSAIDS, bisphosphonates, Gα inhibitors and GGTI potentially
modulate these pathways. (H) Immunotherapy strategies block the inhibitors signals occurring on T-cells, thus reversing the inactivation of immune response against tumor cells. (I) PARP
inhibitors block the repair of SSBs, induced by endogenous damages; cells with functional HR are able to repair more genotoxic DSBs produced by cytotoxic agents, but not BRCA 1 and 2
mutant cells, which undergo cell death. AKT: protein kinase B; Anti-CTLA-4: anti-cytotoxic T-lymphocyte antigen 4; Anti-PD-1: anti-programmed cell death protein 1; AR: androgen receptor;
AURKA: aurora kinase A; CRPC: castration-resistant prostate cancer; ECM: extracellular matrix; ERG: erythroblast transformation-specific related gene-1; ERK: extracellular signal-regulated kinase;
GGTI: inhibitors of geranylgeranyl transferase-1; HIF1α: hypoxia-inducible factor 1-alpha; HSP90: heat shock protein 90; IL-6: interleukin-6; Fzd: frizzled; JAK: janus kinase; JNK: c-Jun N-terminal
kinases; MAPK: mitogen-activated protein kinase; MEK: mitogen-activated protein kinase kinase; mTOR: mammalian target of rapamycin; MYCN: v-myc avian myelocytomatosis viral oncogene
neuroblastoma derived; NEPC: neuroendocrine prostate cancer; NSAIDS: nonsteroidal anti-inflammatory drugs; p53: tumor protein p53; PARP: poly ADP-ribose polymerase; PC: prostate cancer;
PI3K: phosphoinositide 3-kinase; PTEN: phosphatase and tensin homolog; Raf: rapidly accelerated fibrosarcoma; Ras: rat sarcoma; RB: retinoblastoma product; RHOA: ras homolog gene family,
member A; ROCK: rho-associated protein kinase; SMAD: small mother against decapentaplegic; STAT: signal transducer and activator of transcription; TAZ: transcriptional coactivator with PDZ-
binding motif; TKR: tyrosin kinase receptor; TGFβ: transforming growth factor-beta; VEGF: vascular endothelial growth factor; YAP: Yes-associated protein; Wnt: wingless-related integration site.
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of tumor, stromal and immune cells, affecting the progression of PC.
Alterations in the cell structure, shape and polarity support the pro-
liferation and migration of PC cells: several pathways activated during
early stages of embryonic development also play key roles during tu-
morigenesis (Azzolin et al., 2012; Bissell and Hines, 2011; Taipale and
Beachy, 2001; Zanconato et al., 2016b). Cell-surface molecules, growth
and transcription factors are also frequently implicated in the activation
of AR-independent pathways and in the process of epithelial–me-
senchymal transition (EMT). Several studies have assessed drugs which
target these AR-indipendent pathways of survival and have been fo-
cused on unselected, advanced, pluri-treated patients with castration-
resistant prostate cancer (CRPC) (Table 1). However, specific molecular
alterations, alternative to AR, are found in restricted subgroups of pa-
tients and in limited subsets of PC cells. Therefore, initial failures
should not discourage further investigations on these drugs and new
trials should be guided by the accurate identification of patients who
might potentially benefit from these treatments. In addition, ther-
apeutic interventions on these clones should be probably pursued as
early as possible, in order to avoid the praecox selection of AR-in-
different cells, which gradually acquire more and more aggressive
phenotypes.
2. Methods
This manuscript focuses on the results published by the Stand Up To
Cancer – Prostate Cancer Foundation (SU2C-PCF) International Dream
Team in 2015 (Robinson et al., 2015), which revealed the main al-
terations found in patients with metastatic castration-resistant prostate
cancer (mCRPC). An analytical review of literature was implemented to
confirm these findings and to assess the potential clinical implication of
drugs that target these alterations. A systematic search of on-going,
phase I, II and III clinical studies was performed in Feb 2017 on Clin-
icalTrial.gov, PubMed, American Society of Clinical Oncology (ASCO)
and European Society of Medical Oncology (ESMO) web-sites. Given
the wide range of pathways explored, in vitro and in vivo studies were
considered on the basis of their relevance to the topic. The search
strategy included the terms metastatic prostate cancer (mPC), CRPC,
molecular biology, AR, androgen receptor signaling (ARS), phosphoi-
nositide 3-kinase (PI3K), protein kinase B (AKT), mammalian target of
rapamycin (mTOR), poly ADP-ribose polymerase (PARP), wingless-re-
lated integration site (Wnt), mitogen-activated protein kinase (MAPK),
rat sarcoma (RAS), rapidly accelerated fibrosarcoma (Raf), mitogen-
activated protein kinase kinase (MEK), extracellular signal-regulated
kinase (ERK), breast cancer-related gene (BRCA), cyclin-dependent
protein kinases (CDK), androgen-regulated transmembrane protease
serine 2 (TMPRSS2)/erythroblast transformation-specific related gene-
1 (ERG) fusion, Yes-associated protein (YAP), transcriptional coacti-
vator with PDZ-binding motif (TAZ), Notch, Hedgehog (Hh), neuroen-
drocrine prostate cancer (NEPC), aurora kinase A (AURKA), myc avian
myelocytomatosis viral oncogene neuroblastoma derived (MYCN), im-
munotherapy, anti-cytotoxic T-lymphocyte antigen 4 (anti-CTLA-4),
anti-programmed cell death protein 1 (anti-PD-1), vaccines.
3. Kinase-dependent pathways
More than 50% of patients with mCRPC harbor alterations in ki-
nase-dependent signals, involving the PI3K-AKT-mTOR or the MAPK-
ERK pathways (Robinson et al., 2015). Although many efforts have
been carried out in recent years, the majority of tyrosine kinase (TK)
inhibitors (i.e. cabozantinib, dasatinib, sunitinib) or growth factors in-
hibitors (i.e. bevacizumab), that were tested in unselected populations
of patients with PC, proved ineffective (Lorente and De Bono, 2014;
Messina et al., 2016). These failures may be attributed to the lack of
absolute kinase dependency of CRPC and to the rare occurrence of TK
genetic mutations (Grasso et al., 2012; Wyatt and Gleave, 2015). In
addition, bypass signaling, epigenetic events or alterations in down-
stream effectors may also activate these pathways, independently of TK
or growth factors inhibition (Lin and Shaw, 2016). Therefore, many
attempts have been performed to inhibit the downstream checkpoints
of these pathways, rather than the upstream elements.
3.1. PI3K-AKT-mTOR pathway
The PI3K-AKT-mTOR pathway is involved in cell survival, pro-
liferation, differentiation and angiogenesis (Fruman and Rommel,
2014); however, its role in the anchorage-independent growth of tumor
cells and oncogenic ECM remodeling is also well established (Hirsch
et al., 2014). PI3K activation phosphorylates and activates AKT, which
in turn activates mTOR; the phosphatase and tensin homolog (PTEN) is
a tumor suppressor protein, that exerts an inhibitory effect on this
signaling pathway (Luo et al., 2003). In addition, the activation of Twist
induced by AKT represses the E-cadherin-mediated cell to cell adhesion,
thus contributing to the EMT process (Xue et al., 2012). Preclinical data
demonstrated a reciprocal regulation between PI3K and ARS during PC
initiation and progression, pointing to a direct role of PTEN loss and
PI3K/AKT activation in repressing AR expression and activation (Lee
et al., 2015). PI3K-AKT-mTOR thus represents an interesting target to
block a significant number of basic responses leading to PC cells pro-
liferation and dissemination (Bitting and Armstrong, 2013; Hirsch
et al., 2014). Buparlisib, an oral investigational pan PI3K inhibitor,
either alone or when added to AR inhibition, did not improve PFS over
historic control data in men with mCRPC progressing on enzalutamide
(Armstrong et al., 2015). Also PX-866, a pan-isoform inhibitor of class I
PI3K, showed modest activity in docetaxel-naïve CRPC patients (NCIC,
2013). Dactolisib, a novel small molecule, pan-class I PI3K and mTOR
signaling inhibitor was recently tested in a phase I/II trial in combi-
nation with abiraterone acetate in chemo-naïve mCRPC; this trial was
stopped during phase I, due to multiple toxicities (Siegel et al., 2014).
Encouraging results were recently presented by De Bono et al. at the
2016 ESMO Annual Meeting (De Bono et al., 2016a,b). Ipatasertib, an
AKT inhibitor, in combination with abiraterone was compared to
abiraterone alone in a phase II study that enrolled 253 patients with
mCRPC after docetaxel chemotherapy. This combination did not show
statistically significant increased radiologic PFS in the unselected po-
pulation of CRPC compared to abiraterone alone (median 8.2 vs 6.4
months; hazard ratio (HR) = 0.75; p = 0.17). However, a subgroup
analysis revealed that patients with PTEN loss had superior radiologic
PFS benefit when treated with ipatasertib 400 mg compared to those
without PTEN loss (rPFS: 11.5 vs 7.5 months HR:0.39 [0.22–0.70]
p = 0.006) (De Bono et al., 2016a,b). Also, the lowest dosage of ipa-
tasertib (200 mg) in combination with abiraterone determined a rPFS
advantage in patients with PTEN loss compared to those without PTEN
alterations (rPFS: 11.1 vs 4.6 months HR:0.46 [0.22–0.70] p = 0.028).
When PTEN is deleted, AKT regulates PC cells proliferation, while AR
regulates their survival, thus offering a possible explanation of these
results and supporting the rationale of combining AKT blockers with AR
modulators (Sittadjody et al., 2016). This notion has guided a phase I
Table 1
Promising agents targeting AR-independent pathways in patients with PC.
TARGET DRUG REFERENCES
AKT Ipatasertib, AZD5363 (Crabb et al., 2017; De Bono, J. S. et al.,
2016; Kolinsky et al., 2017)
AURKA Alisertib (Beltran et al., 2016a)
Hh Itraconazole (Antonarakis et al., 2013)
Hsp27 Apatorsen (Chi et al., 2017)
mTOR Everolimus (Chow et al., 2016; Gross et al., 2015;
Templeton et al., 2013)
PARP-1 Olaparib, veliparib (Hussain et al., 2016; Mateo et al., 2015)
PD-1 Durvalumab,
pembrolizumab
(Graff et al., 2016a; Hansen et al., 2016;
Karzai et al., 2017)
RAF Sorafenib (Meyer et al., 2014)
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dose-escalation study of enzalutamide in combination with the AKT
inhibitor AZD5363 in heavily pretreated patients with mCRPC
(Kolinsky et al., 2017). AZD5363 at the dosage of 300 mg twice daily
four days on – three days off combined with enzalutamide 160 mg once
daily was well tolerated (only one patient experienced G3 maculo-
papular rash) and this dosage was recommended for the following
phase II trials. Among ten patients who completed 12 weeks of treat-
ment, three met at least one of the criteria for response; in addition, one
patient who had previously progressed on enzalutamide exhibited
partial response, suggesting that AZD5363 may be able to overcome
resistance to enzalutamide. AZD5363 was also investigated in combi-
nation with docetaxel and prednisolone in the ProCAID trial, a phase I
study, which enrolled ten patients with mCRPC (Crabb et al., 2017);
even though this study was not designed to evaluate the efficacy of this
combination, PSA reduction from baseline level to< 50% at 12 weeks
of treatment was seen in seven (70%) of patients. Several compounds
(i.e. temsirolimus, everolimus, ridaforolimus or sapanisertib) have been
developed to specifically inhibit mTOR. Two phase II trials showed
minimal activity of temsirolimus as a single agent both in chemo-naïve
and in docetaxel-treated CRPC patients (Armstrong et al., 2013;
Kruczek et al., 2013). This drug was also tested as maintenance treat-
ment following successful docetaxel chemotherapy, and resulted in a
median time to treatment failure of 24.3 weeks (Emmenegger et al.,
2015). The activity of everolimus, either as monotherapy or in combi-
nation with other drugs, was tested in patients with mCRPC in several
clinical trials (Roviello et al., 2016). A phase II trial assessed single-
agent everolimus in 37 chemotherapy-naive patients with CRPC
(Templeton et al., 2013). Though PTEN loss is correlated with an
overall poor survival (Lotan et al., 2016), patients with PTEN-deficient
tumors treated with this drug showed a trend towards longer PFS and
increased likelihood of response. Given the reciprocal AR-mTOR
crosstalk (Wu et al., 2010), everolimus was tested in combination with
bicalutamide in two phase II trials that recruited patients with CRPC. In
the first one, everolimus was given in combination with bicalutamide
both in chemo-naïve and in docetaxel-treated patients (Nakabayashi
et al., 2012); this trial showed minimal activity of this combination, but
31 out of 36 enrolled patients had already been treated with bicaluta-
mide before trial enrollment, and might therefore suffer from acquired
resistance to this antiandrogen drug. In a more recent trial, the com-
bination of bicalutamide plus everolimus was tested in 24 patients with
CRPC naïve to these drugs (Chow et al., 2016); the treatment arm with
everolimus and bicalutamide was associated with significant toxicity
(58.3% of patients experienced grade 3 or 4 adverse events, as muco-
sitis, hyperglycemia and hematologic toxicity), but also with a decrease
in PSA ≥30% in 75% of patients; this result is quite comparable to that
observed with novel ARS inhibitors (Ryan et al., 2015). Everolimus was
also tested in association with docetaxel (Courtney et al., 2015) and
carboplatin (Vaishampayan et al., 2015), but showed modest activity in
mCRPC. This drug was also evaluated in combination with docetaxel
and bevacizumab in patients with CRPC chemo-naïve (Gross et al.,
2015); this association demonstrated significant clinical activity (max-
imal PSA decline ≥50% achieved in 31 (74%) of patients), but was
associated with several hematologic and non-hematologic grade ≥3
toxicities. A phase II trial also explored the efficacy of everolimus plus
gefitinib, an epidermal growth factor receptor inhibitor, in patients
with CRPC, but did not result in significant antitumor activity
(Rathkopf et al., 2015). Ridaforolimus, another mTOR inhibitor, was
tested as a single agent in 38 patients with taxane-treated mCRPC; this
treatment did not produce objective responses, but stable disease was
observed in 47.4% of patients (Amato et al., 2012). The safety and
tolerability of the combination of ridaforolimus plus bicalutamide was
assessed in a phase I trial (Meulenbeld et al., 2013); although there was
no evidence of a clinically relevant pharmacological drug-drug inter-
action, the occurrence of dose-limiting toxicities in 3/11 evaluable
patients discouraged further studies with this combination. Finally,
sapanisertib (MLN0128), a dual mTOR blocker was tested in a phase II
trial, which recruited nine heavily pretreated patients with mCRPC
(Rathkopf et al., 2016). All patients enrolled had a rise in PSA on
treatment with a median of 159% increase from baseline (range, 12-
620%), while five patients (56%) showed an immediate PSA decline
upon discontinuation of treatment. This observation suggests activation
of the AR in response to dual mTOR inhibition, and confirms the re-
ciprocal link between ARS and PI3K pathways. Recent studies also
suggest that PI3K-AKT-mTOR pathway is intimately connected with
HIF1α, regulating PC stem cells quiescence and metabolism via the
hypoxic signaling (Marhold et al., 2015). Stressful conditions caused by
treatments induce activity of the heat shock proteins (HSP) (i.e. HSP90
and HSP27); these chaperones promote the nuclear transport of the AR
and are essential for the activation of HIF1α and hypoxia pathway
(Minet et al., 1999; Wyatt and Gleave, 2015). HSP90 inhibitors showed
limited activity when administered as monotherapy in patients with
mCRPC (Thakur et al., 2016; Wyatt and Gleave, 2015). Conversely,
apatorsen, an HSP27 inhibitor, showed good tolerability and encoura-
ging activity in a phase I study (Chi et al., 2016) and the recent data
presented at the 2017 Genitourinary Cancers Symposium (ASCO GU)
suggest that apatorsen might overcome the resistance to abiraterone in
patients with mCRPC (Chi et al., 2017). Given the dual blockade of ARS
and hypoxia-inducible factor 1-alpha (HIF1α) by HSP inhibitors, the
biological contribute of the hypoxia signaling to PC progression re-
mains undefined; the exclusive activation of this pathway is probably
relevant only in few PC clones, but these cells might represent the most
undifferentiated and resistant populations. Anthracyclines effectively
inhibit HIF1α (Masoud and Li, 2015); the use of these compounds in PC
has been limited by toxicity and moderate activity, but some responses
have been observed in patients with CRPC (Harris et al., 2002); these
data might provide the rationale to renew interest in these che-
motherapeutics. In conclusion, preclinical studies support the crucial
role of the PI3K/AKT/mTOR pathway in mCRPC, but there is little
evidence of clinical benefit with inhibition of this pathway in un-
selected population of mCRPC. The use of PTEN/AKT/mTOR inhibitors
and/or HIF1α/HSP inhibitors and/or AR modulators may probably be
required for efficient pharmaceutical targeting of the most resistant PC
clones. Further combination strategies might improve the blockade of
this complex pathway, which appears to sustain essential AR-in-
dependent metabolic processes (Qin et al., 2012; Robinson et al., 2015;
Wyatt and Gleave, 2015). However, the identification of the best
combinations of agents depending on the specific characteristics of
patients (i.e. PTEN aberrations) is probably the current challenge to be
faced.
3.2. MAPK-ERK pathway
The MAPK/ERK pathway (also known as the Ras-Raf-MEK-ERK
pathway) is a complex system of signal transduction activated by a wide
variety of growth factors. Though this pathway is found to be altered
only in limited patients with mCRPC (Robinson et al., 2015), its acti-
vation generates extensive changes in gene expression, mediated by
transcription factors that control tumor cells proliferation, differentia-
tion, migration, and invasion as well as angiogenesis (Dhillon et al.,
2007). Whereas activating somatic mutations in the Raf pathway are
common in melanoma, Raf fusions (3% of mCPRC), rather than muta-
tions, are suggested as a mechanism for Raf gene activation in PC
(Palanisamy et al., 2010; Robinson et al., 2015). Several studies in-
vestigated the activity of sorafenib, a Raf inhibitor, both in che-
motherapy-naïve (Chi et al., 2008; Safarinejad, 2010; Steinbild et al.,
2007) and in pretreated unselected populations of patients with mCRPC
(Aragon-Ching et al., 2009; Dahut et al., 2008; Nabhan et al., 2012),
with discouraging results. Recently, Meyer et al. enrolled 21 patients
whose disease had progressed during chemotherapy and added sor-
afenib to their last chemotherapy regimen (Meyer et al., 2014). They
observed biochemical response in 10/21 patients and radiographic
stability in 16/21, suggesting that sorafenib may overcome
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chemotherapy-failure among patients with CRPC. Sorafenib combined
with enzalutamide exerted a synergistic in vivo inhibitory effect both on
AR and ERK pathways; therefore, clinical studies testing sorafenib in
the prevention of resistance to enzalutamide are encouraged (Wu et al.,
2017). Preclinical models showed that combination of MEK inhibitors
with PI3K-AKT-mTOR blockers may exert synergistic activity and effi-
cacy in enzalutamide-resistant CRPC (Park et al., 2015; Toren et al.,
2016). A phase II trial is planned to assess the safety and efficacy of the
MEK 1/2 inhibitor trametinib in men with progressive mCRPC Single-
Arm, in press ,whereas a randomized phase II trial is comparing the
effects of AR inhibition with and without MEK inhibition on the de-
velopment of EMT in PC Randomized Open-label, 2017 Randomized
Open-label, in press, In conclusion, though sorafenib showed limited
activity in unselected populations of CRPC, further studies should
probably clarify the role of Raf and MEK inhibition in overcoming re-
sistance to standard therapies; in addition, selected patients presenting
rearrangements of the Raf gene may benefit from pan-Raf or MEK in-
hibitors.
4. DNA-repair pathway
The accumulation of genetic and epigenetic aberrations char-
acterizes prostate carcinogenesis; these molecular changes can be either
inherited or be the result of altered AR transcriptional activity, changes
in chromatin architecture, oncogenic replication, error-prone DNA re-
pair, or defective cell division (Mateo et al., 2015). Deficient DNA re-
pair response and defective apoptotic checkpoint control can lead to
permanent incorporation of these genome abnormalities, conferring
survival and growth advantage to the transformed cell. Deleterious
germline or somatic aberrations in genes key to the DNA damage repair
pathway (BRCA, CDK12, ATM) were found in 19% and 23% of primary
PCs and mCRPC, respectively (Network, 2015; Robinson et al., 2015).
Recently, Pritchard et al. confirmed that 82 (11.8%) of 692 men with
mPC had at least one presumed pathogenic germline mutation in a gene
involved in DNA-repair processes (Pritchard et al., 2016). Germline
mutations in ataxia telangiectasia mutated (ATM) and BRCA1/2 are
associated with earlier age at death, shorter survival time, and earlier
relapse after local treatments in PC (Castro et al., 2015; Na et al., 2016).
BRCA2 and BRCA1 also represent about 50% of all inherited mutations
and these alterations are associated with higher risk of nodal involve-
ment, distant metastasis, and poor survival outcomes (Castro et al.,
2013). PARP are a family of enzymes involved in the recruitment of
DNA repair effectors and modulate transcription processes (Deshmukh
and Qiu, 2015). When DNA damage is repairable, PARP-1 recruits
proteins involved in DNA repair, whereas when the damage is too se-
vere, the same enzyme leads to cell death (Deshmukh and Qiu, 2015).
PARP inhibitors are effective in cells with impairment of DNA repair
genes (i.e. BRCA mutations) because of the so-called synthetic lethality.
Single strand breaks induced by endogenous damages cannot be ef-
fectively repaired in the presence of PARP inhibitors (O’Connor et al.,
2007); cells with functional homologous recombination are able to re-
pair more genotoxic double strand breaks, but not BRCA 1 and 2 mutant
cells, which undergo cell death (Mateo et al., 2015). Olaparib was the
first PARP inhibitor tested in PC. The phase II study TOPARP-A assessed
the antitumor activity of this drug in 49 patients who had received at
least three lines of therapy for CRPC. Olaparib was well tolerated and
led to response in 14 out of 16 patients who had defects in DNA-repair
genes, included BRCA1/2, ATM, Fanconi's anemia genes, and CHEK2
(Mateo et al., 2015). Based on these results, the TOPARP-B study is
ongoing to prospectively assess the activity of olaparib in patients with
aberrations in DNA repair genes (Mateo et al., 2015;TOPARP, in press).
PARP inhibition synergizes with AR targeted therapy in preclinical
models (Brenner et al., 2011). This is the rationale of a phase II trial that
was designed to evaluate the efficacy of veliparib, another PARP in-
hibitor, plus abiraterone acetate compared to abiraterone acetate alone
in patients with mCRPC stratified basing on erythroblast
transformation-specific (ETS) gene status; the preliminary results of this
combination were presented at the 2016 ASCO Annual Congress
(Hussain et al., 2016). Eighteen (27%) out of 153 randomized patients
had homozygous deletions or deleterious mutations in genes involved
in DNA repair, BRCA 1/2 and ATM included. The subgroup analysis
revealed a better PFS in patients with DNA repair gene alterations as
compared to those with an intact DNA-damage-repair system (13.5
months [95% CI: 8.2–NR] versus 5.8 months [95% CI: 4.2–8.2]). Other
PARP inhibitors, as niraparib and rucaparib, are under investigation in
two phase II (Galahad, TRITON 2) and one phase III (TRITON3) trials,
respectively, which are enrolling patients with mCRPC with or without
impairment of DNA repair genes An Efficacy, 2017 An Efficacy, in press
A Study of Rucaparib, in press Study of Rucaparib, in press. DNA da-
maging agents, as carboplatin, satraplatin and topoisomerase inhibitors
showed limited activity in unselected populations of patients with
CRPC (Birtle et al., 2004; Buonerba et al., 2014; Klein et al., 2002; Sella
et al., 2009; Sternberg et al., 2009). Nevertheless, retrospective ana-
lyses and spurious case reports support the notion that DNA defects
might confer sensitivity to these treatments (Cheng et al., 2016; Kumar
et al., 2016). For this reason, carboplatin monotherapy is considered an
acceptable alternative for heavily pretreated CRPC patients, who
harbor defects in DNA repair genes (Cheng et al., 2016). PARP in-
hibitors are suggested to enhance the antitumor activity of cytotoxic
therapies and overcome acquired resistance to these drugs (O’Connor
et al., 2007; Virag and Szabo, 2002). Veliparib was tested in association
with temozolomide in a pilot study that enrolled pretreated patients
with mCRPC. This combination was well tolerated, but showed limited
activity in this unselected population (Hussain et al., 2014). Of note,
dose-limiting hematological toxicity was reported when olaparib was
combined with chemotherapy in patients with advanced solid tumors
(Balmana et al., 2014; Rajan et al., 2012). Therefore, intermittent ola-
parib with reduced doses of cisplatin was suggested as an alternative
combination to improve tolerability (Balmana et al., 2014). Further
studies are warranted to assess the potential of PARP inhibitors in
combination with cytotoxic agents. For example, olaparib enhanced the
sensitivity of Ewing sarcoma bearing EWSR1-ETS fusions to trabectedin
in vivo (Ordonez et al., 2015), and patients with CRPC who harbor ETS
fusions might be suitable for this combination. EWSR1-ETS fusions
mismatch repair (MMR) – deficient tumors appear to be more re-
sponsive to PD-1 blockade than MMR – proficient tumors (Le et al.,
2015), therefore studies are also needed to assess the role of im-
munotherapy in the context of CRPCs with MMR alterations. Recently,
the anti-PD-1 antibody durvalumab was investigated in combination
with olaparib in a phase II trial which enrolled pretreated patients with
mCRPC (Karzai et al., 2017). This combination was tolerable and led to
PSA response in two out of six patients without BRCA mutation. In
conclusion, many mCRPC patients harbor germline or somatic muta-
tions in genes involved in DNA repair which might be predictive of
response to DNA damaging agents or PARP inhibitors. Thus, DNA
testing warrants clinical consideration in selected subsets of patients.
5. Cell-cycle pathway
Several signals (AR, PI3K-AKT, MAPK, Wnt) are integrated and
processed by the cell-cycle regulatory machinery, which is responsible
of cell division or quiescence (Balk and Knudsen, 2008; Cadoo et al.,
2014). Four CDKs regulate the transitions from G2–M–G1–S phases,
while the RB product is a critical inhibitor of transition from G1–S
phase, preventing premature cell division (Weinberg, 2014). CDKs are
responsible of retinoblastoma product (RB) phosphorylation and/or
inactivation, allowing the cell to proceed or not with division. RB loss is
reported in 21% of CRPCs and is also implicated in neuroendocrine
differentiation of PC (Beltran et al., 2016b; Robinson et al., 2015; Tan
et al., 2014). RB inactivation promotes the reprogramming of differ-
entiated cells to a pluripotent state and this supports the notion that the
selective pressure, induced by ARS inhibitors and chemotherapy, may
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confer stemness-like features to PC cells (Ellis and Loda, 2015; Kareta
et al., 2015). In addition, alterations in genes involved in CDKs reg-
ulation were reported in approximately 14% of CRPC samples
(Robinson et al., 2015). All these alterations may be of clinical interest,
because the use of CDK-inhibitors would prevent RB phosphorylation,
repressing tumor cells proliferation and dedifferentiation (Knudsen and
Wang, 2010). Palbociclib and ribociclib are CDK4/6 inhibitors effective
in the treatment of advanced breast cancer (Finn et al., 2016;
Hortobagyi et al., 2016; Turner et al., 2015). In PC, CDK4/6-specific
inhibition reduced tumor proliferation both in vivo and in ex vivo pri-
mary human tumors (Comstock et al., 2013). Actually, a phase II study
is evaluating the PSA response after treatment with palbociclib plus
ADT, compared to ADT alone, in patients with RB-positive mPC REF: A
Phase II Study of Androgen Deprivation, in press; a phase II study is also
assessing the activity of this CDK inhibitor in an unselected population
of CRPCs A Phase II Study of Palbociclib, in press. Ribociclib is under
investigation in a phase Ib/II trial, that evaluates the PSA response of
ribociclib plus enzalutamide compared to enzalutamide alone in che-
motherapy-naïve mCRPC that retains RB expression Enzalutamide, in
press.
6. Developmental pathways
Processes occurring during tumorigenesis are intimately connected
with those observed during embryogenesis and organogenesis (Aiello
and Stanger, 2016). Wnt, ERG, YAP/TAZ, Hh, and Notch are key reg-
ulators of early development and are also found to be deregulated in
PC. These pathways might thus represent potential therapeutic targets
for the treatment of this neoplasm.
6.1. Wnt pathway
The Wnt pathway is altered in 18% of patients with mCRPC
(Robinson et al., 2015). The Wnt proteins direct cell proliferation and
polarity as well as determine a wide range of embryonic patterning
events (Sharma et al., 2015). Wnt pathway also promotes EMT-like
changes and regulates the expression of factors that are relevant to
metastatic progression, notably metalloproteinases and other regulators
of the ECM (Anastas and Moon, 2013). In prostate, paracrine Wnt sig-
naling is involved in the interactions between stromal and epithelial
cells induced by transforming growth factor-beta (TGFβ), modulating
androgen sensitivity of epithelial cells (Placencio et al., 2008). In the
absence of Wnt ligands, β-catenin is recruited into a destruction com-
plex, comprised of adenomatous polyposis coli (APC) and axin, which
induces the phosphorylation of β-catenin by casein kinase 1 and gly-
cogen synthase kinase 3. After activation of the Wnt canonical pathway,
β-catenin escapes proteasomal degradation, accumulates in the cyto-
plasm and subsequently translocates to the nucleus, where it activates
the transcription of Wnt target genes (Lai et al., 2009). R-spondins
potentiate Wnt ligand activity as either coactivators or inhibitors of Wnt
signaling receptor degradation (Jin and Yoon, 2012). Recurrent al-
terations of APC, β-catenin and R-spondin are observed in mCRPC pa-
tients (Robinson et al., 2015), supporting the role of this pathway in PC
progression. The term non-canonical Wnt pathway has been used in the
literature to refer to Wnt-activated signal transduction independent of
β-catenin stabilization (Lai et al., 2009). β-Catenin-independent Wnt
pathways have been proposed to regulate cell polarity and migration,
including metastasis (Lai et al., 2009). The RNA-Seq of single prostate
circulating tumor cells (CTCs) suggested the strong involvement of non-
canonical Wnt signaling in antiandrogen resistance (Miyamoto et al.,
2015) and the suppression of its key downstream components, such as
Rho kinase, restored partial sensitivity to antiandrogen therapy in vitro
(Rath and Olson, 2012). Ursolic acid, a Wnt inhibitor, exerted in vitro
antitumor activity and has also been suggested as a chemotherapeutic
agent in PC patients (Park et al., 2013). Other studies showed that
Mesd, a LRP5/6 co-receptor inhibitor, effectively inhibits PC cells
proliferation (Lu et al., 2010) and neutralizing antibodies to Wnt3a
reversed PC cells tumorigenesis (Li et al., 2008). Some polyphenols,
such as quercetin, epigallocatechin-3-gallat, curcumin and resveratrol,
limited PC cell proliferation in in vitro models acting on Wnt signaling;
however, their potential clinical implication is controversial (Jasinski
et al., 2013). Non-steroidal anti-inflammatory drugs, such as sulindac
and celecoxib block the Wnt signaling, decreasing nuclear compart-
mentalization or enhancing localization of β-catenin to the plasma
membrane (Clapper et al., 2004; Lu et al., 2009). Clinical trials in-
vestigated the efficacy of celecoxib and sulindac in combination with
chemotherapy in unselected populations of patients with CRPCs, but
these drugs did not add any benefit to chemotherapy alone (Carles
et al., 2007; Kattan et al., 2016; Ryan et al., 2005; Sinibaldi et al.,
2006). Small-molecule therapeutics or even biologics that target the
Wnt pathway are still in their infancy and therefore further studies are
warranted to understand the potential anti-tumor activity of Wnt
pathway inhibition (Kahn, 2014).
6.2. TMPRSS2/ERG and Hippo pathway
In 2005, Tomlins et al. reported a recurrent chromosome re-
arrangement in PC, involving the genes TMPRSS2, localized on chro-
mosome 21q23.2, and ERG, an ETS-related gene localized on chromo-
some 21q22.2 (Tomlins et al., 2005). Subsequently, the SU2C-PCF
International Dream Team confirmed that TMPRSS2/ERG fusion, re-
sulting in ERG overexpression, is observed in about 40% of advanced
PC (Robinson et al., 2015). ERG protein is involved in embryonic de-
velopment, vascular integrity, cell proliferation, and apoptosis (Han
et al., 2015). Several studies investigated the predictive and prognostic
role of this aberration in PC. TMPRSS2/ERG fusion was found in per-
ipheral blood mononuclear cells from patients with mCRPC and was
associated with resistance to docetaxel and worse prognosis (Reig et al.,
2016). Attard et al. suggested that the presence of TMPRSS2/ERG re-
arrangement in CTCs of mCRPC patients may be predictive of sensi-
tivity to treatment with abiraterone (Attard et al., 2009); in contrast,
Danila et al. did not find a correlation between TMPRSS2/ERG status in
CTCs and response to abiraterone (Danila et al., 2011). PARP enzymes
are necessary for ERG-mediated PC progression and ETS fusion-positive
xenografts were shown sensitive to PARP inhibitors in vitro (Brenner
et al., 2011). Upon this basis, a phase II trial is evaluating the efficacy of
abiraterone plus veliparib compared to abiraterone alone in men with
mCRPC stratified for the presence or absence of the TMPRSS2-ERG
fusion Abiraterone, in press. Unfortunately, the preliminary results of
this trial presented at the 2016 ASCO Annual Congress (Hussain et al.,
2016) do not suggest that TMPRSS2-ERG fusion is predictive of re-
sponse to this combination. Given the supposed sensitivity of TMPRSS2-
ERG tumors to histone deacetylase inhibitors (Iljin et al., 2006), a phase
II trial evaluated the efficacy of pracinostat in an unselected population
of 32 CRPC patients (7/21 evaluable patients presented TMPRSS2/ERG
fusion), but this drug showed limited activity in this setting of patients
(Eigl et al., 2015). Celastrol, a NF-kB inhibitor, was effective in redu-
cing the growth of TMPRSS2/ERG expressing PC in vitro and in vivo
(Shao et al., 2013), but currently no clinical trial testing this drug is
planned. Recently, Nguyen et al. demonstrated that ERG activates the
YAP transcriptional program and induces the development of age-re-
lated prostate tumors in mouse models (Nguyen et al., 2015). This re-
sult provided direct genetic evidence of a causal role for ERG in PC and
revealed a connection between ERG and the Hippo signaling pathway.
YAP and TAZ, the main effectors of the Hippo pathway, can reprogram
cancer cells into cancer stem cells and incite tumor initiation, pro-
gression and metastasis (Piccolo et al., 2014; Zanconato et al., 2016b).
TAZ also serves as a downstream element of the Wnt pathway (Azzolin
et al., 2012). These transcriptional regulators are transducers of cellular
structural features, such as polarity, shape and cytoskeletal organiza-
tion. In turn, these features are strictly connected to the cell's location in
within the tridimensional architecture of tissues, including the
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attachment to other cells and to the ECM (Zanconato et al., 2016b).
First reports in 2007 showed that PC tissues have significant elevation
of YAP protein levels and these data are confirmed by in vitro studies
(Sheng et al., 2015; Zhang et al., 2015; Zhao et al., 2007). Tankyrase
inhibitors, statins, bisphosphonates, geranylgeranyl transferase-1 and
G-proteins inhibitors are suggested as modulators of YAP/TAZ pathway
(Zanconato et al., 2016a); however, the pharmacological inhibition of
this pathway remains challenging, as many interactions specifically
involved in the control of YAP/TAZ activity may be difficult to target
(Zanconato et al., 2016a).
6.3. Hh and Notch pathways
Hh signaling, as well as Wnt pathway, is suggested to modulate stem
cells characteristics (Kalderon, 2002; Taipale and Beachy, 2001). In PC,
Hh cascade regulates epithelial–mesenchymal interactions, cell sur-
vival, angiogenesis and metastatic potential of cells (Karhadkar et al.,
2004). Antonarakis et al. evaluated the efficacy of high-dose itracona-
zole, an Hh pathway inhibitor, in men with metastatic chemotherapy-
untreated CRPC; this drug showed modest clinical activity, as suggested
by longer PFS times than in historical data (Antonarakis et al., 2013).
TAK-441 and vismodegib are selective Smo antagonists and delayed
progression of PC in vivo models, by disrupting paracrine hedgehog
signaling (Ibuki et al., 2013; Karlou et al., 2012); some trials are on-
going to assess the efficacy of vismodegib in men with CRPC
Leuprolide, in press A Study of Vismodegib, in press. Also, two small-
molecule antagonists of Hh pathway inhibithed PC proliferation in in
vitro and in vivo models, but no clinical application has yet been tested
(Lauth et al., 2007). Notch signaling is another developmental pathway,
which regulates organogenesis, cell death and tissue homeostasis (Su
and Xin, 2016). Notch synergizes with several pathways, as AKT, Wnt,
Ras/Raf/MAPK, and contributes to the development and progression of
PC (Stoyanova et al., 2016). Both tumor suppressive and oncogenic
roles of Notch have limited the investigation of Notch inhibitors for PC
and probably more studies are needed to understand the therapeutic
potential of this signaling pathway (Su and Xin, 2016; Yuan et al.,
2015).
7. Neuroendrocrine differentiation
Neuroendocrine differentiation of PCs is estimated to drive ap-
proximately 25% of the nearly 34,000 cases of lethal PC in the United
States per year (Jemal et al., 2011). Divergent clonal evolution from
one or more CRPC adenocarcinoma cells has been suggested as the
main mechanism of development of NEPC (Beltran et al., 2016b). With
the growing clinical use of ARS inhibitors, a subset of resistant tumors
shows reduced or absent AR expression and small-cell carcinoma or
neuroendocrine features (chromogranin A, synaptophysin and neural
cell adhesion molecule) on metastatic biopsy (Beltran et al., 2011;
Palmgren et al., 2007; Watson et al., 2015). Molecular profiling of
NEPC has revealed loss of RB1, PTEN and tumor protein p53 (p53)
mutations as well as amplification of MYCN and AURKA (Beltran et al.,
2011; Tan et al., 2014). Unfortunately, the development of NEPC is
associated with a poor survival of patients due to lack of effective
treatments available (Mosquera et al., 2013). Based on the clinical ef-
ficacy observed in neuroendocrine lung cancer, the use of platinum-
based chemotherapy has been suggested in NEPC; however, this treat-
ment strategy is characterized by a high response rate of short duration
(Aparicio et al., 2013). Recently, Beltran et al. evaluated the activity
and safety of alisertib, an AURKA inhibitor, in a phase II study, that
enrolled 59 patients with metastatic NEPC (Beltran et al., 2016a). Based
on the previously developed integrated 70-gene NEPC classifier
(Beltran et al., 2016b), they showed high correlation of molecular al-
terations (AURKA/MYCN, AR signaling, RB1/TP53) with clinical-pa-
thological features and exceptional responders. Although the trial did
not meet its primary endpoint, which was PFS, the authors concluded
that a specific subset of patients with clinical-pathologically defined
NEPC may benefit from alisertib monotherapy. MYCN levels are regu-
lated by bromodomain and extra-terminal proteins (BET) proteins and
the BET inhibitors were effective in reducing the growth of CRPC in
vitro and in vivo (Asangani et al., 2014; Wyce et al., 2013). In addition,
BET inhibitors were recently shown to enhance the efficacy and disrupt
resistance to AR antagonists in CRPCs, providing a compelling rationale
to combine BET inhibitors with AR antagonists in clinical trials
(Asangani et al., 2016).
8. Tumor microenvironment and immunotherapy
Normal tissue homeostasis and architecture physiologically inhibit
cancer development and progression; therefore, tumor expansion and
dissemination assumes an impaired control of all those transcriptional
regulators that are modulated by a complex interchange of information
among cells in the local microenvironment (Bissell and Hines, 2011).
The ECM provides not only architectural support, but also chemical and
mechanical cues to cells; several proteins (i.e. periostin, tenascin-C,
versican), growth factors (i.e. TGFβ, epidermal growth factor, vascular
endothelial growth factor, hepatocyte growth factor), interleukins as
well as ECM stiffness influence the tumor microenvironment (Barron
and Rowley, 2012; Bonnans et al., 2014; Nuzzo et al., 2014; Pickup
et al., 2013). All these factors modulate PC cell proliferation and induce
EMT through multiple signals, including the JAK-STAT, the SMAD, the
MAPK and the PI3K pathway (Nguyen et al., 2014; Pickup et al., 2013).
The serum levels of interleukin-6 and TGFβ are associated with PC
progression, metastases and poor survival of patients (Shariat et al.,
2004; Shariat et al., 2011). These markers are surrogated of chronic
inflammation and a potential link between prostatitis, prostatic infec-
tions and the development of PC was suggested (Sfanos and De Marzo,
2012). Differently from melanoma and other neoplasms, which show
high rates of somatic mutations and are considered good targets for
immunotherapy, the mutational load of PC cells has been historically
considered low (Schumacher and Schreiber, 2015). However, growing
evidence suggests that mCRPC show higher mutational load compared
with primary tumors (Drake, 2010; Robinson et al., 2015; Taylor et al.,
2010). Many immunotherapy approaches share the common goal of
inducing a specific T-cell response directed against the tumor cells and
reversing their resistance to adaptive immunity (Drake, 2010; Ribas,
2015). The first successful achievement in PC immunotherapy was the
development of Sipuleucel-T. This cell-based vaccine was approved in
2010 by the U.S. Food and Drug Administration for the treatment of
mCRPC, given a 4-month OS improvement reported in the phase III trial
IMPACT, which randomized 512 patients with mCRPC in a 2:1 ratio to
receive either Sipuleucel-T or placebo (Kantoff et al., 2010). Based on
this, Sipuleucel-T is widely included among the treatment options for
patients with minimally symptomatic or asymptomatic mCRPC NCCN,
2017. Nevertheless, the Society for Immunotherapy of Cancer under-
scores that there is still no absolute consensus on the utilization of Si-
puleucel-T regarding several aspects, including sequencing im-
munotherapy with other treatments and monitoring of response, and
that recommendations still need to be improved (McNeel et al., 2016).
In particular, in an era when several new ARS inhibitors are becoming
increasingly available for the treatment of mCRPC, an interesting
challenge will be to fit the use of Sipuleucel-T in the most appropriate
temporal frame over the disease course, and to select the optimal subset
of patients that may derive a greater benefit from it. Moreover, even
though a direct cost comparison with other agents is difficult, especially
over the complete course of treatment, Sipuleucel-T represents an ex-
pensive option. Some other vaccines achieved promising results in
mCRPC patients in phase I/II trials, with mild side effects, and many
others are currently under investigation (Cattrini et al., 2016). For ex-
ample, the randomized, phase III trials VIABLE Phase III, in press and
PROSPECT Randomized and Double-blind, in press are ongoing to
evaluate the efficacy and safety of a dendritic-cell based vaccine
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(DCVAC/PCa) and of a vector-based vaccine (PROSTVAC), respectively,
in men with mCRPC eligible for first-line chemotherapy. Even though
initial phase I/II trials showed promising results with the use of the
anti-CTLA-4 antibody ipilimumab (Cha and Small, 2013), a randomized
phase III trial failed to show an OS benefit when this agent was used
alone for patients with mCRPC in the post-docetaxel setting (Kwon
et al., 2014). Nevertheless, in a retrospective subgroup analysis of this
study, OS was 22.7 months among a small cohort of ipilimumab-treated
patients with favorable prognostic features (namely, patients with non-
visceral disease, alkaline-phospatase< 1.5 times the upper limit of
normal and hemoglobin of at least 11.5 g/dL) as compared to 15.8
months in the placebo group. Also, ipilimumab did not improve OS in
patients with chemotherapy-naive mCRPC in a phase III trial that en-
rolled 598 patients to receive ipilimumab or placebo (2:1) (Beer et al.,
2016). Two phase I trials evaluated the activity of the anti-PD-1 anti-
body nivolumab as a single agent in heavily pre-treated advanced
malignancies, but failed to show objective responses in the PC cohort
(Brahmer et al., 2010; Topalian et al., 2012). The Keynote-028 Study
was designed to evaluate the safety and efficacy of the anti-PD-1
pembrolizumab monotherapy in PD-L1-positive advanced solid tumor
cohorts (Hansen et al., 2016). The preliminary results from the PC co-
hort of this phase 1b study (23 patients) reported an ORR of 13%, but
45% of evaluable patients had a decrease from baseline in the sum of
longest diameters of target lesions. Exploratory assessment of the re-
lationship between gene expression profile score and clinical outcome
revealed the putative T cell inflamed signature to be associated with
better clinical outcome (Hansen et al., 2016). Bishop et al. observed
that resistance to enzalutamide is associated with the strong expression
of anti-PD-1 therapy targets in circulating immune cells both in mCRPC
patients and in pre-clinical models (Bishop et al., 2015). On this basis,
Graff et al. treated 20 mCRPC patients who progressed on enzalutamide
with pembrolizumab 200 mg IV every 3 weeks for 4 doses (Graff et al.,
2016a); of note, pembrolizumab was added to and did not replace the
standard dose of enzalutamide. 20% of patients (4/20) showed re-
markable long-lasting PSA responses and 35% (7/20) had stable disease
ranging 9-50 weeks (Graff et al., 2016b). In vitro studies support that
ADT may sensitize prostate cancer cells to T-cell killing through an-
drogen receptor dependent modulation of the apoptotic pathway
(Ardiani et al., 2014). These clinical data confirm that primary and
secondary ADT may stimulate T cell infiltrates, synergizing with im-
munotherapeutics. In addition, the genetic analysis of two responders
revealed markers of microsatellite instability in one patient, suggesting
that patients with DNA repair genes alterations may also be candidates
to these treatments (Graff et al., 2016b). Recent data also revealed that
bone metastases from PC, with low AR expression and reduced meta-
bolic activity, show high MHC class I expression and immune cell in-
filtration; this supports the rationale for treating specific PC patients
with combinations of ADT and immunotherapy (Ylitalo et al., 2016). In
conclusion, to date there are no prospective data to support mono-
therapy with either an anti-CTLA-4 or anti-PD-1 agents in patients with
mCRPC. However, these immunotherapeutics appear to be effective in
specific subgroups of patients; probably, the identification of synergies
with ARS inhibitors or other drugs, as well as their correct im-
plementation in the sequence of agents currently used in CRPC, may
uncover unexpected potentialities of these new compounds. This notion
is guiding the experimental design of new trials, such as the Keynote-
199 study, which is recruiting 250 men with mCRPC to assess the ac-
tivity of pembrolizumab in patients previously treated with che-
motherapy Study of Pembrolizumab, in press; this study has three
planned cohorts: participants with PD-L1-positive, measurable disease;
participants with PD-L1 negative, measurable disease; participants with
bone-metastases, non-measurable disease. The discovery of novel bio-
markers of response may also help the selection of those cases candi-
dates for immunotherapy.
9. Conclusions
The majority of treatments that are currently used in clinical prac-
tice to treat patients with PC modulate the ARS pathway. The increased
heterogeneity, phenotypic plasticity, and genomic variability of PC cells
in the setting of advanced disease are frequently responsible of re-
sistance to treatment. Several studies suggest that AR is still activated
after progression on AR-directed therapies and that it still plays a role in
advanced and heavily pretreated CRPC. However, many pathways, both
AR related and non-AR related, can contribute to progression of CRPC.
In some cases, AR-independent pathways provide sustenance for the
growth of aggressive tumor cells with high metastatic potential. Many
non-AR-directed drugs have been tested in CRPC, mostly as mono-
therapy or in unselected populations of patients, and studies yielded
conflicting results. Predictive markers of response are therefore needed
to avoid the failure of future trials, and to properly select patients that
would most likely benefit from non-AR-targeted therapies. For example,
in the years to come, liquid biopsies might help identify these subsets of
patients, offering new therapeutic opportunities for those with poor
baseline prognostic features or primary as well as acquired resistance to
hormone-therapies. In addition, studies evaluating combinations of ARS
modulators or chemotherapy with compounds that target AR-in-
dependent pathways may provide new insight on the treatment options
for both early and advanced PC.
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